Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients

Silvia Riondino, Natalia Petrini, Luciamaria Donato, Concetta Torromeo, Gaetano Tanzilli, Fabio M. Pulcinelli, Francesco Barillà

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Statin interference has been suggested among the mechanisms of reduction of the antiplatelet effect of clopidogrel. We thus sought to assess the influence of rosuvastatin on clopidogrel antiplatelet action in high-risk (HR) cardiovascular patients. To set the level of platelet inhibition by combined antithrombotic treatments we retrospectively studied two populations of HR patients, one under aspirin alone, the other under aspirin plus rosuvastatin, before and after addition of clopidogrel. The effects of rosuvastatin compared with atorvastatin were then prospectively investigated in patients who underwent percutaneous coronary intervention (PCI), under clopidogrel and aspirin treatment. Light transmission platelet aggregation (LTA) was studied in response to adenosine diphosphate (ADP) (5 μM) or arachidonic acid (0.5 mM). The inhibitory effect of clopidogrel in reducing ADP-induced LTA was similar in the two HR groups of patients. No difference in ADP-induced platelet aggregation was observed in the two PCI groups of patients with either atorvastatin or rosuvastatin. In conclusion, rosuvastatin does not interfere with the antiplatelet effect of clopidogrel in patients with cardiovascular disease.

Original languageEnglish
Pages (from-to)151-155
Number of pages5
JournalJournal of Thrombosis and Thrombolysis
Volume28
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

clopidogrel
Blood Platelets
Platelet Aggregation
Adenosine Diphosphate
Aspirin
Percutaneous Coronary Intervention
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Light
Arachidonic Acid
Rosuvastatin Calcium
Cardiovascular Diseases

Keywords

  • Aspirin
  • Clopidogrel
  • Platelet aggregation
  • Rosuvastatin

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. / Riondino, Silvia; Petrini, Natalia; Donato, Luciamaria; Torromeo, Concetta; Tanzilli, Gaetano; Pulcinelli, Fabio M.; Barillà, Francesco.

In: Journal of Thrombosis and Thrombolysis, Vol. 28, No. 2, 2009, p. 151-155.

Research output: Contribution to journalArticle

Riondino, S, Petrini, N, Donato, L, Torromeo, C, Tanzilli, G, Pulcinelli, FM & Barillà, F 2009, 'Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients', Journal of Thrombosis and Thrombolysis, vol. 28, no. 2, pp. 151-155. https://doi.org/10.1007/s11239-008-0254-6
Riondino, Silvia ; Petrini, Natalia ; Donato, Luciamaria ; Torromeo, Concetta ; Tanzilli, Gaetano ; Pulcinelli, Fabio M. ; Barillà, Francesco. / Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. In: Journal of Thrombosis and Thrombolysis. 2009 ; Vol. 28, No. 2. pp. 151-155.
@article{fc59cf3f113246c696da077c857ebedf,
title = "Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients",
abstract = "Statin interference has been suggested among the mechanisms of reduction of the antiplatelet effect of clopidogrel. We thus sought to assess the influence of rosuvastatin on clopidogrel antiplatelet action in high-risk (HR) cardiovascular patients. To set the level of platelet inhibition by combined antithrombotic treatments we retrospectively studied two populations of HR patients, one under aspirin alone, the other under aspirin plus rosuvastatin, before and after addition of clopidogrel. The effects of rosuvastatin compared with atorvastatin were then prospectively investigated in patients who underwent percutaneous coronary intervention (PCI), under clopidogrel and aspirin treatment. Light transmission platelet aggregation (LTA) was studied in response to adenosine diphosphate (ADP) (5 μM) or arachidonic acid (0.5 mM). The inhibitory effect of clopidogrel in reducing ADP-induced LTA was similar in the two HR groups of patients. No difference in ADP-induced platelet aggregation was observed in the two PCI groups of patients with either atorvastatin or rosuvastatin. In conclusion, rosuvastatin does not interfere with the antiplatelet effect of clopidogrel in patients with cardiovascular disease.",
keywords = "Aspirin, Clopidogrel, Platelet aggregation, Rosuvastatin",
author = "Silvia Riondino and Natalia Petrini and Luciamaria Donato and Concetta Torromeo and Gaetano Tanzilli and Pulcinelli, {Fabio M.} and Francesco Barill{\`a}",
year = "2009",
doi = "10.1007/s11239-008-0254-6",
language = "English",
volume = "28",
pages = "151--155",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients

AU - Riondino, Silvia

AU - Petrini, Natalia

AU - Donato, Luciamaria

AU - Torromeo, Concetta

AU - Tanzilli, Gaetano

AU - Pulcinelli, Fabio M.

AU - Barillà, Francesco

PY - 2009

Y1 - 2009

N2 - Statin interference has been suggested among the mechanisms of reduction of the antiplatelet effect of clopidogrel. We thus sought to assess the influence of rosuvastatin on clopidogrel antiplatelet action in high-risk (HR) cardiovascular patients. To set the level of platelet inhibition by combined antithrombotic treatments we retrospectively studied two populations of HR patients, one under aspirin alone, the other under aspirin plus rosuvastatin, before and after addition of clopidogrel. The effects of rosuvastatin compared with atorvastatin were then prospectively investigated in patients who underwent percutaneous coronary intervention (PCI), under clopidogrel and aspirin treatment. Light transmission platelet aggregation (LTA) was studied in response to adenosine diphosphate (ADP) (5 μM) or arachidonic acid (0.5 mM). The inhibitory effect of clopidogrel in reducing ADP-induced LTA was similar in the two HR groups of patients. No difference in ADP-induced platelet aggregation was observed in the two PCI groups of patients with either atorvastatin or rosuvastatin. In conclusion, rosuvastatin does not interfere with the antiplatelet effect of clopidogrel in patients with cardiovascular disease.

AB - Statin interference has been suggested among the mechanisms of reduction of the antiplatelet effect of clopidogrel. We thus sought to assess the influence of rosuvastatin on clopidogrel antiplatelet action in high-risk (HR) cardiovascular patients. To set the level of platelet inhibition by combined antithrombotic treatments we retrospectively studied two populations of HR patients, one under aspirin alone, the other under aspirin plus rosuvastatin, before and after addition of clopidogrel. The effects of rosuvastatin compared with atorvastatin were then prospectively investigated in patients who underwent percutaneous coronary intervention (PCI), under clopidogrel and aspirin treatment. Light transmission platelet aggregation (LTA) was studied in response to adenosine diphosphate (ADP) (5 μM) or arachidonic acid (0.5 mM). The inhibitory effect of clopidogrel in reducing ADP-induced LTA was similar in the two HR groups of patients. No difference in ADP-induced platelet aggregation was observed in the two PCI groups of patients with either atorvastatin or rosuvastatin. In conclusion, rosuvastatin does not interfere with the antiplatelet effect of clopidogrel in patients with cardiovascular disease.

KW - Aspirin

KW - Clopidogrel

KW - Platelet aggregation

KW - Rosuvastatin

UR - http://www.scopus.com/inward/record.url?scp=67849083185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67849083185&partnerID=8YFLogxK

U2 - 10.1007/s11239-008-0254-6

DO - 10.1007/s11239-008-0254-6

M3 - Article

C2 - 18636229

AN - SCOPUS:67849083185

VL - 28

SP - 151

EP - 155

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 2

ER -